Concepedia

Bh3 Profiling

BH3 Profiling is a functional assay methodology that distinguishes cellular apoptotic readiness by measuring the mitochondrial response to synthetic BH3 peptides, thereby identifying dependencies on specific anti-apoptotic BCL-2 family proteins.

52

Publications

6.2K

Citations

503

Authors

166

Institutions

Publications per year

2017–2026

28

Parents

Publications

52

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri et al. · Cancer Discovery · 2016 · 1.1K citations · Full text

, , +17

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

Rongqing Pan, Leah J. Hogdal, Juliana M. Benito et al. · Cancer Discovery · 2013 · 735 citations · Full text

, , +17

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737

Victoria Del Gaizo Moore, Jennifer R. Brown, Michael Certo et al. · Journal of Clinical Investigation · 2007 · 596 citations · Full text

, , +13

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

Tríona Ní Chonghaile, Kristopher A. Sarosiek, Thanh-Trang T. Vo et al. · Science · 2011 · 587 citations

, , +17

BH3 Profiling Identifies Three Distinct Classes of Apoptotic Blocks to Predict Response to ABT-737 and Conventional Chemotherapeutic Agents

Jing Deng, Nicole E. Carlson, Kunihiko Takeyama et al. · Cancer Cell · 2007 · 506 citations · Full text

, , +13

1–5 of 52

Authors

503

  1. AL
    Anthony Letai

    Dana-Farber Cancer Institute, United States

    23 publications · 5K citations

    21

    h-index

  2. JR
    Jeremy Ryan

    Dana-Farber Cancer Institute, United States

    13 publications · 2.4K citations

    13

    h-index

  3. JM
    Joan Montero

    Dana-Farber Cancer Institute, United States

    6 publications · 456 citations

    6

    h-index

  4. RM
    Richard M. Stone

    Dana-Farber Cancer Institute, United States

    6 publications · 2.9K citations

    6

    h-index

  5. MS
    Matthew S. Davids

    Dana-Farber Cancer Institute, United States

    5 publications · 389 citations

    5

    h-index

1–5 of 503

Institutions

166

  1. Dana-Farber Cancer Institute

    Boston, United States

    23 h-index

    181 publications

    50.6K citations

  2. Harvard University

    Cambridge, United States

    17 h-index

    84 publications

    27.4K citations

  3. Brigham and Women's Hospital

    Boston, United States

    9 h-index

    18 publications

    2.8K citations

  4. The University of Texas MD Anderson Cancer Center

    Houston, United States

    6 h-index

    59 publications

    29.5K citations

  5. Broad Institute

    Cambridge, United States

    5 h-index

    11 publications

    633 citations

  6. AbbVie (United States)

    North Chicago, United States

    4 h-index

    55 publications

    38K citations

  7. University of Nottingham

    Nottingham, United Kingdom

    4 h-index

    17 publications

    294 citations

  8. Nottingham University Hospitals NHS Trust

    Nottingham, United Kingdom

    3 h-index

    9 publications

    174 citations

1–8 of 166

Venues

  1. Cancer Discovery

    5 publications · 2.7K citations

    5

    h-index

  2. Journal of Clinical Investigation

    JCI · 3 publications · 684 citations

    3

    h-index

  3. Cell Death and Disease

    3 publications · 101 citations

    3

    h-index

  4. Clinical Cancer Research

    3 publications · 159 citations

    3

    h-index

  5. PLoS ONE

    3 publications · 54 citations

    3

    h-index

1–5